company background image
GRF logo

Grifols BME:GRF Stock Report

Last Price

€9.23

Market Cap

€5.8b

7D

0.2%

1Y

-30.5%

Updated

22 Jul, 2024

Data

Company Financials +

Grifols, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Grifols
Historical stock prices
Current Share Price€9.23
52 Week High€15.92
52 Week Low€6.36
Beta0.67
11 Month Change1.18%
3 Month Change6.58%
1 Year Change-30.54%
33 Year Change-55.46%
5 Year Change-68.59%
Change since IPO251.54%

Recent News & Updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21
Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21
Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20
Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04
Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01
Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Feb 20
Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Jan 09
Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Nov 10
Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20
Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Is Grifols (BME:GRF) A Risky Investment?

Aug 03
Is Grifols (BME:GRF) A Risky Investment?

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

May 18
Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

Shareholder Returns

GRFES BiotechsES Market
7D0.2%0.3%-0.5%
1Y-30.5%-27.1%13.7%

Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned -27.6% over the past year.

Return vs Market: GRF underperformed the Spanish Market which returned 13.3% over the past year.

Price Volatility

Is GRF's price volatile compared to industry and market?
GRF volatility
GRF Average Weekly Movement7.6%
Biotechs Industry Average Movement7.5%
Market Average Movement3.0%
10% most volatile stocks in ES Market6.0%
10% least volatile stocks in ES Market0.7%

Stable Share Price: GRF has not had significant price volatility in the past 3 months.

Volatility Over Time: GRF's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
190923,000Nacho Abia Buenachewww.grifols.com

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.

Grifols, S.A. Fundamentals Summary

How do Grifols's earnings and revenue compare to its market cap?
GRF fundamental statistics
Market cap€5.83b
Earnings (TTM)€189.00m
Revenue (TTM)€6.66b

33.2x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRF income statement (TTM)
Revenue€6.66b
Cost of Revenue€4.09b
Gross Profit€2.56b
Other Expenses€2.37b
Earnings€189.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)0.28
Gross Margin38.51%
Net Profit Margin2.84%
Debt/Equity Ratio140.3%

How did GRF perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.